- active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Argentina · Australia · Belgium - active not recruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
United States · Belgium · Canada - recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · China - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE1, PHASE2
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This study is testing a new experimental medicine, AZD5863, for people with advanced stomach, oesophageal, or pancreatic cancer. It aims to see if the medicine is safe, what dose works best, and if it can help fight the cancer.
United States · China · France - active not recruitingPHASE2
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
This study looks at whether a daily low-dose aspirin can stop Barrett's oesophagus from coming back after successful treatment. We're also checking how safe aspirin is and tracking specific body markers that might show if the condition is returning.
United States · Canada - recruitingPHASE1
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
This study is testing a new combination treatment for stomach or gullet cancer that can be removed with surgery. It combines a drug called Tislelizumab with standard chemotherapy (FLOT) given before the operation. We want to see if this new approach is safe and works well.
Germany - recruitingNA
RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
This study compares two keyhole surgeries for a type of oesophageal cancer. It looks at traditional keyhole surgery versus keyhole surgery using a robot, to see which removes more affected lymph nodes. The aim is to find out if robotic surgery is better for patients.
Germany - active not recruitingPHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.
United States · France · Germany - recruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
United States · Belgium · China